MedTrace Logo

Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT00623558 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2013-12-04

No results posted yet for this study

Summary

The aim of the study is to investigate the efficacy and safety of cetuximab, docetaxel, cisplatin combination as induction therapy in locally advanced head and neck squamous cell carcinoma.

Conditions

  • Head and Neck Neoplasm

Interventions

DRUG

Cetuximab

400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks

DRUG

Docetaxel

75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)

DRUG

Cisplatin

75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)

Sponsors & Collaborators

  • Clinical Research Center for Solid Tumor, Korea

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Dae Seog Heo, Prof. · Clinical Research Center for Solid Tumors, Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-11-30
Completion
2013-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00623558 on ClinicalTrials.gov